MONTREAL, September 17th, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the publication of an updated invited review article on REP 2139 in the journal ACS Infectious Diseases (https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.8b00156).
This updated review of REP 2139 entitled “REP 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV infection” forms part of a special issue on Challenges and Opportunities in Hepatitis B. This review includes a detailed examination of the biochemistry underlying the antiviral effects of REP 2139, a summary of data from publications and clinical studies and the next steps in the development of REP 2139.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.